Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas —a randomized controlled trial (PRIMA)
This study evaluates the potential benefit of a universal radical cure for bothP. vivax andP. falciparum in different endemic locations. If found safe and effective universal radical cure could represent a cost-effective approach to clear otherwise unrecognisedP. vivax infections and hence accelerateP. vivax elimination.Trial registrationNCT03916003. Registered on 12 April 2019. (Source: Trials)
Source: Trials - May 18, 2022 Category: Research Source Type: clinical trials
Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
Condition: Malaria, Vivax Interventions: Other: Training on revised algorithm; Other: Enhancing Pharmacovigilance; Other: Supervision of malaria services in selected facilities.; Diagnostic Test: G6PD testing; Drug: Tafenoquine; Drug: Primaquine; Other: Follow Up Visit at Day 3 [+2 days] after treatment sta rt Sponsors: Medicines for Malaria Venture; Universidad Peruana Cayetano Heredia; UNITAID; ICON plc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 4, 2022 Category: Research Source Type: clinical trials
